(CORT) Corcept Therapeutics - Ratings and Ratios

Corcept Therapeutics Incorporated (NASDAQ:CORT) is a biopharmaceutical company specializing in the discovery, development, and commercialization of therapies for severe endocrine, oncologic, metabolic, and neurologic disorders. The companys lead product, Korlym (mifepristone), is approved for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushings syndrome who have type 2 diabetes mellitus or glucose intolerance and are either ineligible for or have failed surgery. Korlym functions as a cortisol receptor antagonist, addressing the underlying hormonal imbalance in Cushings syndrome.

The companys pipeline includes multiple late-stage clinical programs. Relacorilant, a selective cortisol receptor antagonist, is in Phase III trials for hypercortisolism and is being investigated in combination with nab-paclitaxel for platinum-resistant ovarian cancer. Additional Phase I/II studies are evaluating relacorilant for adrenal cancer and cortisol excess. The company is also exploring the use of dazucorilant, a next-generation cortisol receptor antagonist, in Phase II trials for amyotrophic lateral sclerosis (ALS), and miricorilant, another selective cortisol receptor antagonist, in Phase IIb trials for metabolic dysfunction-associated steatohepatitis (NASH).

Corcept Therapeutics, founded in 1998 and headquartered in Redwood City, California, has established itself as a leader in cortisol receptor antagonism, with a focus on addressing unmet medical needs in endocrine and metabolic disorders. The companys strategic approach combines precision medicine with a robust clinical development pipeline to expand its therapeutic offerings.

Ticker Symbol: CORT
Exchange: NASDAQ
Type: common stock
Country Origin: United States
GICS Sub Industry: Pharmaceuticals

Resistance: 100.0
Support: 69.1
Support: 59.8
Support: 50.7
Support: 46.1

Average Volume 20d: 1,682,804
Last Price: 71.79
SMA 20: 72.10
SMA 50: 65.23
SMA 200: 51.71
ATR: 7.05

Market Cap: $6,566.51M USD
P/E: 50.60
P/E Forward: 37.74
P/B: 9.66
P/S: 9.73
RoE: 20.70

3-Month Forecast:
Based on the convergence of and , CORT is expected to test the resistance level at 100.0, driven by strong earnings and pipeline momentum. The stock is likely to consolidate above the SMA 50 (65.23) with potential pullbacks to 59.8. The ATR of 7.05 suggests moderate volatility, with upside capped near 85.0 in the near term. The P/S ratio of 9.73 indicates premium valuation, but robust revenue growth from Korlym and advancing clinical trials may justify multiples. Support at 46.1 remains a key floor.